治疗成人复发或难治性多发性骨髓瘤新药：免疫偶联物belantamab mafodotin

doi:10.3969/j.issn.2095-1264.2022.06.05

首页 > 过刊浏览>2022年第6期 >709-713. DOI:10.3969/j.issn.2095-1264.2022.06.05

治疗成人复发或难治性多发性骨髓瘤新药：免疫偶联物belantamab mafodotin
DOI:
                        10.3969/j.issn.2095-1264.2022.06.05
                    
作者:
                        
                        
                    
作者单位:亳州市人民医院 静配中心，安徽 亳州，236800
作者简介:狄潘潘，男，硕士，主管药师，研究方向：药学。
通讯作者:
中图分类号:R733.3;R730.51
基金项目:

New drug for the treatment of adult relapsed or refractory multiple myeloma: immunoconjugate belantamab mafodotin

Author:

Affiliation:

Pharmacy Intravenous Admixture Services, Bozhou People’s Hospital, Bozhou, 236800, Anhui, China

Fund Project:

摘要

图/表

访问统计

参考文献

相似文献

引证文献

资源附件

文章评论

摘要:

belantamab mafodotin（BLENREP）是由GlaxoSmithKline公司研发的靶向抗肿瘤药物，可选择性作用于恶性浆细胞表面的B细胞成熟抗原。该药于2020年8月5日获美国食品药品监督管理局（FDA）批准上市，用于治疗成人复发或难治性多发性骨髓瘤。临床试验表明，belantamab mafodotin具有较好的临床疗效，常见不良反应包括角膜病变、血小板减少症及贫血。本文主要对belantamab mafodotin的作用机制、用法用量、药动学、临床研究及不良反应等方面进行介绍，以期为临床用药提供一定的参考。

Abstract:

Belantamab mafodotin (BLENREP) is a targeted anti-tumor drug developed by GlaxoSmithKline. It can selectively act on B cell maturation antigens on the surface of malignant plasma cells. The drug was approved by the U.S. Food and Drug Administration (FDA) on August 5, 2020 for the treatment of relapsed or refractory multiple myeloma in adults. Clinical trials have shown that belantamab mafodotin has good clinical effects. Its common adverse reactions include corneal disease, thrombocytopenia and anemia. In this paper, we mainly introduced the mechanism of action, dosage, pharmacokinetics, clinical research and adverse reactions of belantamab mafodotin, in order to provide some reference for clinical medication.